| 12.83 0.05 (0.39%) | 01-27 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 15.18 | 1-year : | 17.73 |
| Resists | First : | 13 | Second : | 15.18 |
| Pivot price | 12.22  |
|||
| Supports | First : | 11.66 | Second : | 10.84 |
| MAs | MA(5) : | 12.55 |
MA(20) : | 12.05 |
| MA(100) : | 13.11  |
MA(250) : | 11.64 |
|
| MACD | MACD : | 0.1 |
Signal : | 0 |
| %K %D | K(14,3) : | 90.1 |
D(3) : | 87.5 |
| RSI | RSI(14): 60.8 |
|||
| 52-week | High : | 76 | Low : | 5.55 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.[ INKT ] has closed below upper band by 7.3%. Bollinger Bands are 41.6% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 2 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 12.84 - 12.88 | 12.88 - 12.92 |
| Low: | 12.37 - 12.42 | 12.42 - 12.47 |
| Close: | 12.75 - 12.82 | 12.82 - 12.9 |
MiNK Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. Its product candidate is AGENT-797, an off-the-shelf, allogeneic for iNKT cell therapy and treatment of various myeloma diseases, which is in Phase 1 clinical trials. The company was formerly known as AgenTus Therapeutics, Inc. MiNK Therapeutics, Inc. was incorporated in 2017 and is based in New York, New York. MiNK Therapeutics, Inc. operates as a subsidiary of Agenus Inc.
Sun, 11 Jan 2026
MiNK Therapeutics (NASDAQ:INKT) Downgraded by Wall Street Zen to "Sell" - MarketBeat
Thu, 08 Jan 2026
Trial tests cell therapy to prevent life-threatening transplant complication - Stock Titan
Fri, 14 Nov 2025
MiNK Therapeutics Reports Promising Clinical Data and Leadership Expansion Amid Ongoing Development of iNKT Cell Therapies - Quiver Quantitative
Fri, 14 Nov 2025
MiNK Therapeutics Reports Q3 2025 Results and Accelerates - GlobeNewswire
Sun, 09 Nov 2025
The "Off-the-Shelf" Revolution: How iNKT Cell Therapy agenT-797 is Reprogramming the Fight Against Solid Tumors - Oncodaily
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 5 (M) |
| Shares Float | 2 (M) |
| Held by Insiders | 63.5 (%) |
| Held by Institutions | 1.9 (%) |
| Shares Short | 33 (K) |
| Shares Short P.Month | 39 (K) |
| EPS | -3.01 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | -2.95 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -69.7 % |
| Return on Equity (ttm) | 0 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -2.61 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -6 (M) |
| Levered Free Cash Flow | -5 (M) |
| PE Ratio | -4.27 |
| PEG Ratio | 0 |
| Price to Book value | -4.37 |
| Price to Sales | 0 |
| Price to Cash Flow | -10.79 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|